{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:39:13Z","timestamp":1790285953769,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Atrial fibrillation (AF) increases the risk of ischemic stroke (IS) and systemic embolism, necessitating thromboprophylaxis with direct oral anticoagulants (DOAC), which increase bleeding. Drugs that inhibit factor XI (FXI) have been developed to provide thromboprophylaxis with lower bleeding risk. We performed a systematic review and meta-analysis of randomised controlled trials comparing FXI inhibitors versus DOAC in patients with AF, reporting primary outcomes of International Society of Thrombosis and Haemostasis (ISTH) major bleeding or clinically relevant non-major bleeding (CRNMB), and exploratory outcomes of ischaemic stroke (IS), intracranial hemorrhage (ICH) and death. Three trials were identified. The PACIFIC-AF (Phase 2) and OCEANIC-AF (Phase 3) trials compared asundexian, an oral, small-molecule FXIa inhibitor, with apixaban. AZALEA-TIMI 71 (Phase 2) compared abelacimab, a subcutaneous monoclonal antibody against FXI\/FXIa, with rivaroxaban. FXI inhibitors reduced the composite of major bleeding or CRNMB (pooled-OR 0.39, 95%CI 0.30\u20130.50,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0005), major bleeding (OR 0.30, 95%CI 0.22\u20130.41,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004) and CRNMB (pooled-OR 0.44, 95% CI 0.36\u20130.55,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0004) compared to DOAC. Effects were consistent across sex, clinical risk factors and concomitant antiplatelet therapy. Exploratory analyses showed FXI inhibitor use was associated with greater risk of IS (OR 3.37, 95%CI 2.18\u20135.19,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001), similar rate of ICH and lower all-cause mortality (OR 0.82, 95%CI 0.71\u20130.94,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02) than DOAC. Compared to DOAC, FXI inhibitors significantly reduced major bleeding or CRNMB. Exploratory analyses indicate similar risk of ICH, but possible increased IS risk with FXI inhibitors compared to DOAC. Results from ongoing trials will help determine the relative usefulness of FXI inhibitors in patients with AF.\n                  <\/jats:p>","DOI":"10.1007\/s11239-025-03142-x","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:55:09Z","timestamp":1751565309000},"page":"761-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety of factor XI inhibitors compared to factor X inhibitors in atrial fibrillation: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"58","author":[{"given":"Rafaella I. L.","family":"Markides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sogol","family":"Koolaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua H.","family":"Leader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"3142_CR1","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"ICV Gelder","year":"2024","unstructured":"Gelder ICV, Rienstra M, Bunting KV et al (2024) 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS). Eur Hear J 45:3314\u20133414","journal-title":"Eur Hear J"},{"key":"3142_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"JL Halperin","year":"2014","unstructured":"Halperin JL, Hankey GJ, Wojdyla DM et al (2014) Efficacy and safety of Rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban once daily, oral, direct factor Xa Inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 130:138\u2013146","journal-title":"Circulation"},{"key":"3142_CR3","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"key":"3142_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"3142_CR5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955\u2013962","journal-title":"Lancet"},{"key":"3142_CR6","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jama.2017.1152","volume":"317","author":"TS Potpara","year":"2017","unstructured":"Potpara TS, Lip GYH (2017) Postapproval observational studies of Non\u2013Vitamin K antagonist oral anticoagulants in atrial fibrillation. JAMA 317:1115\u20131116","journal-title":"JAMA"},{"key":"3142_CR7","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis M, Hirsch J, Kotler A et al (2017) Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 129:1210\u20131215","journal-title":"Blood"},{"key":"3142_CR8","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","volume":"111","author":"O Salomon","year":"2008","unstructured":"Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U (2008) Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 111:4113\u20134117","journal-title":"Blood"},{"key":"3142_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","volume":"3","author":"X WANG","year":"2005","unstructured":"WANG X, CHENG Q, XU L et al (2005) Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 3:695\u2013702","journal-title":"J Thromb Haemost"},{"key":"3142_CR10","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","volume":"113","author":"EI Tucker","year":"2009","unstructured":"Tucker EI, Marzec UM, White TC et al (2009) Prevention of vascular graft occlusion and thrombus-associated thrombin generation by Inhibition of factor XI. Blood 113:936\u2013944","journal-title":"Blood"},{"key":"3142_CR11","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","volume":"33","author":"JR Crosby","year":"2013","unstructured":"Crosby JR, Marzec U, Revenko AS et al (2013) Antithrombotic effect of antisense factor XI oligonucleotide treatment in Primates. Arter Thromb Vasc Biol 33:1670\u20131678","journal-title":"Arter Thromb Vasc Biol"},{"key":"3142_CR12","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood.V104.11.3501.3501","volume":"104","author":"D Gailani","year":"2004","unstructured":"Gailani D, Cheng Q, Xu L, Ogletree M, Wang X (2004) Effect of factor XI or factor IX deficiency on an arterial occlusion model. Blood 104:3501","journal-title":"Blood"},{"key":"3142_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","volume":"78","author":"C Hsu","year":"2021","unstructured":"Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI (2021) Factor XI Inhibition to uncouple thrombosis from hemostasis. J Am Coll Cardiol 78:625\u2013631","journal-title":"J Am Coll Cardiol"},{"key":"3142_CR14","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s11239-024-02985-0","volume":"57","author":"AE Ali","year":"2024","unstructured":"Ali AE, Becker RC (2024) The foundation for investigating factor XI as a target for Inhibition in human cardiovascular disease. J Thromb Thrombolysis 57:1283\u20131296","journal-title":"J Thromb Thrombolysis"},{"key":"3142_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s11239-024-02972-5","volume":"57","author":"AE Ali","year":"2024","unstructured":"Ali AE, Becker RC (2024) Factor XI: structure, function and therapeutic Inhibition. J Thromb Thrombolysis 57:1315\u20131328","journal-title":"J Thromb Thrombolysis"},{"key":"3142_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"3142_CR17","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ et al (2022) Safety of the oral factor XIa inhibitor asundexian compared with Apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 399:1383\u20131390","journal-title":"Lancet"},{"key":"3142_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa2407105","volume":"392","author":"JP Piccini","year":"2025","unstructured":"Piccini JP, Patel MR, Steffel J et al (2025) Asundexian versus Apixaban in patients with atrial fibrillation. N Engl J Med 392:23\u201332","journal-title":"N Engl J Med"},{"key":"3142_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1056\/NEJMoa2406674","volume":"392","author":"CT Ruff","year":"2025","unstructured":"Ruff CT, Patel SM, Giugliano RP et al (2025) Abelacimab versus Rivaroxaban in patients with atrial fibrillation. N Engl J Med 392:361\u2013371","journal-title":"N Engl J Med"},{"key":"3142_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.thromres.2024.03.001","volume":"236","author":"J Vassart","year":"2024","unstructured":"Vassart J, Didembourg M, Morimont L et al (2024) Asundexian in atrial fibrillation: can pharmacodynamic data explain the failure? Thromb Res 236:236\u2013239","journal-title":"Thromb Res"},{"key":"3142_CR21","doi-asserted-by":"publisher","first-page":"e00963","DOI":"10.1002\/prp2.963","volume":"10","author":"PC Wong","year":"2022","unstructured":"Wong PC, Crain E (2022) Calibration and validation of the rabbit model of electrolytic-mediated arterial thrombosis against the standard\u2010of\u2010care anticoagulant Apixaban. Pharmacol Res Perspect 10:e00963","journal-title":"Pharmacol Res Perspect"},{"key":"3142_CR22","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1182\/blood.V108.11.4130.4130","volume":"108","author":"JM Luettgen","year":"2006","unstructured":"Luettgen JM, Bozarth TA, Bozarth JM et al (2006) In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor. Blood 108:4130","journal-title":"Blood"},{"key":"3142_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/jth.15588","volume":"20","author":"PC Wong","year":"2022","unstructured":"Wong PC, Crain EJ, Bozarth JM et al (2022) Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor xia: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits. J Thromb Haemost 20:399\u2013408","journal-title":"J Thromb Haemost"},{"key":"3142_CR24","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/jth.15700","volume":"20","author":"S Heitmeier","year":"2022","unstructured":"Heitmeier S, Visser M, Tersteegen A et al (2022) Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost 20:1400\u20131411","journal-title":"J Thromb Haemost"},{"key":"3142_CR25","doi-asserted-by":"publisher","first-page":"102276","DOI":"10.1016\/j.rpth.2023.102276","volume":"8","author":"TCL Kohs","year":"2024","unstructured":"Kohs TCL, Vu HH, Jordan KR et al (2024) Activation of coagulation FXI promotes endothelial inflammation and amplifies platelet activation in a nonhuman primate model of hyperlipidemia. Res Pr Thromb Haemost 8:102276","journal-title":"Res Pr Thromb Haemost"},{"key":"3142_CR26","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1182\/blood.2023022257","volume":"144","author":"C Puy","year":"2024","unstructured":"Puy C, Moellmer SA, Pang J et al (2024) Coagulation factor XI regulates endothelial cell permeability and barrier function in vitro and in vivo. Blood 144:1821\u20131833","journal-title":"Blood"},{"key":"3142_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","volume":"44","author":"RD Caterina","year":"2022","unstructured":"Caterina RD, Prisco D, Eikelboom JW (2022) Factor XI inhibitors: cardiovascular perspectives. Eur Hear J 44:280\u2013292","journal-title":"Eur Hear J"},{"key":"3142_CR28","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/europace\/euac020","volume":"24","author":"DA Gorog","year":"2022","unstructured":"Gorog DA, Gue YX, Chao T-F et al (2022) Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A position paper from the ESC working group on thrombosis, in collaboration with the European heart rhythm association, the association for acute cardiovascular care and the Asia-Pacific heart rhythm society. Europace 24:1844\u20131871","journal-title":"Europace"},{"key":"3142_CR29","unstructured":"Anon https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_en.pdf"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03142-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:18:43Z","timestamp":1781608723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03142-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3142"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03142-x","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"19 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RILM, SG, JHL have no disclosures to declare. MF reports proctorship and speaker fees from Meril, Abbott and Biosensors, and previous speaker fees from Medtronic, AstraZeneca, and Chiesi. DAG reports previous institutional research grant from Bayer, Medtronic and AstraZeneca, speaker\u2019s fees from Chiesi, advisory board for Janssen, BMS and Chiesi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}